Understanding how mitochondrial inheritance affects outcomes in blood disorders after stem-cell transplants
Official title: Prognostic implications of mitochondrial inheritance in myelodysplastic syndromes after stem-cell transplantation
Funded at Medical College of Wisconsin · NIH-11061782 · Data updated 2026-11-12
This study is looking at how the DNA from your mitochondria might help doctors better understand and predict outcomes for patients with myelodysplastic syndromes who have had stem-cell transplants, so they can provide more personalized and effective care.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical College of Wisconsin NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project start | April 20, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $156,600 |
| NIH project number | 5K01HL164972-03 |
| Project ID | NIH-11061782 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with myelodysplastic syndromes who are considering or have undergone allogeneic hematopoietic stem-cell transplantation.
✕Less likely to help
Patients with MDS who are not candidates for stem-cell transplantation or those with other unrelated blood disorders may not benefit from this research.
What this research studies
This research investigates the role of mitochondrial DNA in patients with myelodysplastic syndromes (MDS) who have undergone stem-cell transplantation. It aims to identify genetic and epigenetic markers that could predict patient outcomes more accurately than current models, which primarily focus on non-genetic factors. By analyzing mitochondrial inheritance patterns, the study seeks to improve prognostic assessments and tailor treatment approaches for better patient care. The research will utilize advanced omics technologies to gather and analyze data related to mitochondrial function and its impact on hematopoietic health.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment strategies for patients with MDS, potentially improving survival rates and quality of life after stem-cell transplantation.
How similar studies have gone: Previous research has shown that genetic factors, including mitochondrial DNA variations, can influence treatment outcomes in hematologic diseases, suggesting that this approach has potential for success.
Where this research is happening
-
Medical College of Wisconsin
Milwaukee, United States Active
Researchers
- Principal investigator: Dong, Jing — Medical College of Wisconsin
- Study coordinator: Dong, Jing
Related research
Other NIH-funded projects on the same topics.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Whole-genome sequencing to refine risk in myelodysplastic syndromes (MDS) for older adults
This project uses clinical whole-genome sequencing to improve genetic profiling and better predict how MDS will progress in older patients.
-
Targeting gasdermin D to treat myelodysplastic syndromes in people with bone marrow inflammation
A research project aims to find new ways to treat myelodysplastic syndromes by blocking a protein (gasdermin D) involved in harmful bone marrow inflammation.
-
Understanding why some MDS patients relapse after a stem cell transplant
A study of patients with myelodysplastic syndromes after stem cell transplant to learn the cellular changes and gene activity that lead to relapse, with the goal of guiding future treatments.
-
Risk factors and inflammation biomarkers for cardiovascular disease in older adults with myelodysplastic syndromes
A study focuses on older adults with myelodysplastic syndromes to understand why they have higher cardiovascular risk and how inflammatory proteins in the blood might help predict it.
-
Therapeutic targeting of transcription-epigenetic defects in SF3B1-mutant MDS
A training-focused grant to help a clinician-scientist develop therapies for adults with a common bone marrow failure condition called SF3B1-mutant myelodysplastic syndrome (MDS).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.